Comparator sourcing: Leveraging the Bolar exemption to accelerate market access for generic and biosimilar products

In the coming decade, many of today’s top-selling biopharmaceuticals will be coming off-patent – creating huge opportunities for generics and biosimilars developers.

Find out how to overcome market access issues by successfully using the Bolar exemption, a provision that exists in different forms across many regionalities and allows for the preparation of generics and biosimilars ahead of originators' patent expirations.

Don’t miss your free insights into leveraging the Bolar exemption. Download your free white paper from Scrip, presented in partnership with Thermo Fisher Scientific.

Download your free white paper to explore:

Specificities and challenges of navigating pharmaceutical patents
The Bolar exemption - definition and patent implications
Regional differences in Bolar and Bolar-like provisions
Leveraging these exemptions to accelerate market access for generics and biosimilars

Whitepaper

Complete the form below to download the content.

* - marks a required field

Email Address

First Name

Last Name

Address

City

Country

Province

State

Post Code

Phone

Answer the following questions about your organization below:

Company Name

How many people are employed by your organization?

What is your company's revenue?

In which industry do you work?

Job Function

Job Title

Job Level

Department

By clicking ‘Submit’ you agree to our Terms of Use. We take your privacy seriously. For more information please read our Privacy Policy.